Trial reportThe Journal of clinical investigation2014
Germinal center reentries of BCL2-overexpressing B cells drive follicular lymphoma progression.
Trial report in The Journal of clinical investigation, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 108 citations in OpenAlex.
- Subclonal TP53 mutations are frequent and predict resistance to radioimmunotherapy in follicular lymphoma.Blood advances · 2023Trial
- FOXP1 expression is a prognostic biomarker in follicular lymphoma treated with rituximab and chemotherapy.Blood · 2018Trial
- SPEN Loss Drives Extrafollicular Diffuse Large B-cell Lymphoma with Female-Specific Lethality and Therapeutic Vulnerabilities.Cancer discovery · 2026Article
- Article
- miR-155 aberrant expression impairs tumor rejection because of its targeting of ICOSL and multiple pathways implicated in the antitumor response.Pharmacological reviews · 2026Review
- Article
- Biology as vulnerability in follicular lymphoma: genetics, epigenetics, and immunogenetics.Blood · 2025Review
- B lymphoproliferative diseases: Effective treatment, inhibited progression, and potential cures through isoform-specific targeting of the prolactin receptor.Vitamins and hormones · 2025Review
- Follicular lymphoma research: an open dialogue for a collaborative roadmap.Histopathology · 2025Review
- Characterization of Human B Cell Hematological Malignancies Using Protein-Based Approaches.International journal of molecular sciences · 2024Review
- ARID1A orchestrates SWI/SNF-mediated sequential binding of transcription factors with ARID1A loss driving pre-memory B cell fate and lymphomagenesis.Cancer cell · 2024Article
- Article
- Mutations associated with progression in follicular lymphoma predict inferior outcomes at diagnosis: Alliance A151303.Blood advances · 2023Article
- Tracing Founder Mutations in Circulating and Tissue-Resident Follicular Lymphoma Precursors.Cancer discovery · 2023Article
- Oxidative Stress and Inflammation in B-Cell Lymphomas.Antioxidants (Basel, Switzerland) · 2023Review
- Lymphoma-associated mutations in autoreactive memory B cells of patients with Sjögren's syndrome.The Journal of pathology · 2023Article
- Review
- Modeling the crosstalk between malignant B cells and their microenvironment in B-cell lymphomas: challenges and opportunities.Frontiers in immunology · 2023Review
- Advances in the multi-omics landscape of follicular lymphoma.International journal of biological sciences · 2023Review
- Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023Review
8 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
32 authors at 3 institutions in 1 country.
Funding
Abstract
It has recently been demonstrated that memory B cells can reenter and reengage germinal center (GC) reactions, opening the possibility that multi-hit lymphomagenesis gradually occurs throughout life during successive immunological challenges. Here, we investigated this scenario in follicular lymphoma (FL), an indolent GC-derived malignancy. We developed a mouse model that recapitulates the FL hallmark t(14;18) translocation, which results in constitutive activation of antiapoptotic protein B cell lymphoma 2 (BCL2) in a subset of B cells, and applied a combination of molecular and immunofluorescence approaches to track normal and t(14;18)(+) memory B cells in human and BCL2-overexpressing B cells in murine lymphoid tissues. BCL2-overexpressing B cells required multiple GC transits before acquiring FL-associated developmental arrest and presenting as GC B cells with constitutive activation-induced cytidine deaminase (AID) mutator activity. Moreover, multiple reentries into the GC were necessary for the progression to advanced precursor stages of FL. Together, our results demonstrate that protracted subversion of immune dynamics contributes to early dissemination and progression of t(14;18)(+) precursors and shapes the systemic presentation of FL patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.